Medications for Alcohol Use Disorder in Patients with Liver Disease: Leveraging an Underutilized Tool

5 (1 vote)

  • Register
    • Administrative Staff - Free!
    • Counselor (CAADE, CADTP, CCAPP, LPC, LMHC NCC, etc.) - Free!
    • PhD - Free!
    • Nurse (MSN, LPN, RN, LVN) - Free!
    • Nurse Practitioner (APRN, DNP) - Free!
    • Pharmacist (PharmD) - Free!
    • Physician (MD) - Free!
    • Physician (DO) - Free!
    • Physician (MBBS) - Free!
    • Physician Associate (PA-C) - Free!
    • Psychologist (PsyD) - Free!
    • Social Worker (MSW, LCSW, LGSW) - Free!
    • Student/Resident/Fellow - Free!
    • Other - Free!

Medications for Alcohol Use Disorder in Patients with Liver Disease: Leveraging an Underutilized Tool

Host: National Council for Mental Wellbeing

Recorded: June 26, 2024


Enduring Training

Overview

Mortality due to alcohol-related liver disease (ALD) has risen steadily over the past two decades, with a sharp increase during the COVID-19 pandemic. In 2022, 46% of liver disease deaths among people ages 12 and older involved alcohol. Despite alcohol’s role in liver disease deaths, medication treatments for alcohol use disorder (MAUD) are rarely used in patients with ALD, in part because of stigma, limited data on effectiveness, and concerns about safety and further potential damage to the liver. There is an immense opportunity to increase use of MAUD for patients with or at risk of liver disease to tackle co-occurring health needs and prevent further complications or even death. This course out the benefits of prescribing MAUD for patients with or at risk of liver disease, as well as how to safely do so. 

The target audience for this introductory level activity includes: All prescribers and clinicians

Learning Objectives

Upon completion, learners will be able to:

  1. Outline the benefits of MAUD for patients with or at risk of liver disease.
  2. Describe barriers to MAUD treatment for patients with or at risk of liver disease and explore ways to address these.
  3. Discuss safe MAUD implementation among patients with liver disease.

Need Assistance?

For assistance logging in, accessing activities, claiming credit, or for other questions or concerns, please check the FAQ page, or contact pcss@asam.org.

Lamia Haque, MD, MPH

Hepatologist, Addiction Medicine Specialist, Assistant Professor of Internal Medicine

Yale School of Medicine

No relevant financial disclosures.

Gene Im, MD, FAASLD

Transplant Hepatologist, Associate Professor of Medicine

Mount Sinai Icahn School of Medicine



No relevant financial disclosures.

Disclosure Information

In accordance with the disclosure policies of ASAM and Joint Accreditation, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all accredited continuing education activities. These policies include identifying and mitigating all relevant financial relationships with ineligible companies for those involved in the creation and dissemination of accredited continuing education.

This activity is not for credit.

Certificate of Completion

Upon completion of the activity and online evaluation,  participants may request a certificate of participation. Participants may submit this certificate of participation to their professional organization/institute as documentation for completing this activity.

Key:

Complete
Failed
Available
Locked
View On-Demand Session
Open to view video.
Open to view video. This video is approximately 60 minutes and was recorded June 26 2024.
Complete Evaluation
Select the "Complete Evaluation" button to begin.  |  10 minutes
Select the "Complete Evaluation" button to begin.  |  10 minutes Complete this evaluation: https://ttc-gpra.org/P?s=116522.
Claim Certificate of Completion
No credits available  |  Certificate available
No credits available  |  Certificate available